[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of the Punjab\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":247},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,91,103,126,160,185,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053733","impact-of-behavioural-modification-working-toolkit-among-women-with-gestational-diabetes-mellitus-and-hypertension-100053733",false,"NCT07551011","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 15-49 years.\n* Gestational age between 16 and 20 weeks at enrolment.\n* Diagnosed with both gestational diabetes mellitus (GDM) and pregnancy-induced hypertension (PIH).\n* At least one prior antenatal visit at the study site.\n\nExclusion Criteria:\n\n* Pre-existing diabetes mellitus or chronic hypertension prior to pregnancy.\n* Pre-existing renal disease, thyroid disease, or major hematological disorders.\n* Multiple pregnancy (e.g., twins, triplets).\n* Severe psychiatric illness.","FEMALE","15 Years","49 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial aims to evaluate the effectiveness of a Behavioral Modification Working (BMW) Toolkit in improving glycemic control and blood pressure among pregnant women diagnosed with both GDM and PIH.",[27,28],"Gestational Diabetes Mellitus in Pregnancy","Hypertension ,Pregnancy",[30,31,32,33,34,35,36,37,38,39],"Gestational Diabetes Mellitus","Pregnancy Induced Hypertension","Maternal health","Childbirth","Risk Factors","intervention","BMW Toolkit","Dietary habits","Physical activity","sleep pattern","RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2026-04-21",{"date":48,"type":21},"2027-01-15",{"name":50,"class":51},"University of the Punjab","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100632622","feasibility-trial-of-a-correctional-management-for-juvenile-offenders-100632622","NCT07516080","Feasibility Trial of a Correctional Management for Juvenile Offenders","Inclusion Criteria:\n\n1. Male juvenile offenders aged 11 to 17 years\n2. Currently residing in a correctional institution\n3. Able to understand Urdu and participate in group-based sessions\n4. Provide informed assent\n\nExclusion Criteria:\n\n1. Presence of a severe psychiatric condition requiring immediate or intensive clinical treatment\n2. Significant cognitive impairment or developmental condition that limits ability to engage in the intervention\n3. Currently receiving another structured psychological or behavioral intervention\n4. Medical or behavioral condition that would interfere with safe participation, as determined by institutional staff or the researcher","MALE","11 Years","17 Years",{"count":63,"type":21},60,[24],"The goal of this clinical trial is to learn if a structured Correctional Management intervention can be feasibly implemented with incarcerated juveniles in a correctional institution. It will also assess whether the research procedures can be successfully carried out with this population.\n\nThe main questions it aims to answer are:\n\n1. Can participants be effectively recruited, retained, and engaged, and can the intervention be delivered acceptably with adequate therapist adherence and complete outcome data collection?\n2. Does the intervention demonstrate preliminary effectiveness? Researcher will compare an experimental (intervention) group to a control group receiving standard institutional management to see if the intervention can be practically delivered and is associated with initial changes in outcomes.\n\nParticipants will:\n\n1. Be randomly assigned to either the intervention group or the control group\n2. Complete assessments at baseline (before the intervention) and post-intervention\n3. Attend structured intervention sessions (if assigned to the experimental group)\n4. Complete standardized self-report measures assessing emotional and behavioral difficulties, psychological capital, criminal thinking styles, attitudes toward seeking mental health services, emotion regulation, and moral disengagement",[67],"Juvenile Delinquency",[69,70,71,72,73,74,75,76,77,78,79,80,81],"Juvenile offenders","Incarcerated Juveniles","delinquency","juvenile delinquent","feasibility trial","rct","randomized controlled trial","correctional management","psychological intervention","behavioral intervention","Youth in detention","adolescents","pilot study","2026-06-24",{"date":84,"type":44},"2026-06-29",{"date":86,"type":44},"2026-03-11",{"date":88,"type":21},"2026-06-30",{"name":50,"class":51},1,{"id":92,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":25,"conditions":95,"keywords":96,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":102,"locationsCount":52},"100635309",{"count":20,"type":21},[24],[27,28],[30,31,32,33,34,35,36,37,38,39],"2026-04-24",{"date":99,"type":44},"2026-04-30",{"date":46,"type":21},{"date":48,"type":21},{"name":50,"class":51},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100629051","efficacy-of-cognitive-stimulation-therapy-integrated-with-stress-reduction-intervention-for-adults-with-mild-cognitive-impairment-100629051","NCT07469618","Efficacy of Cognitive Stimulation Therapy Integrated With Stress Reduction Intervention for Adults With Mild Cognitive Impairment","Inclusion Criteria:\n\n* Adults aged 45 years and above\n* Individuals with education up to Matric\n* Individuals who obtain a score lower than 23 on Montreal Cognitive Assessment (MoCA) suggesting the presence of cognitive decline.\n* Individuals who obtain a score of 14 or more on the Perceived Stress Scale suggesting increased levels of perceived stress (moderate and high)\n* Individuals who obtain score ranged from 13 to 25 (Poor to Adequate) on Quality of Life in Alzheimer's Disease (Qol-AD)\n\nExclusion Criteria:\n\n* Diagnosis of dementia or major neurocognitive disorder\n* Presence of severe psychiatric illness (e.g., psychosis, major depressive episode)\n* Significant hearing or visual impairments that interfere with participation\n* Currently undergoing psychological or cognitive therapy\n* Any neurological condition that may interfere with cognitive assessment (e.g., stroke, Parkinson's disease)","ALL","45 Years",{"count":112,"type":21},12,[24],"The aim of this study is to determine if integrating a culturally congruent indigenous stress reduction intervention into Cognitive Stimulation Therapy (CST) enhances cognitive outcomes in Pakistani adults with Mild Cognitive Impairment (MCI).",[116],"Mild Cognitive Impairment (MCI)","NOT_YET_RECRUITING","2026-03-10",{"date":120,"type":44},"2026-03-13",{"date":122,"type":21},"2026-03",{"date":124,"type":21},"2026-06",{"name":50,"class":51},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":109,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100605082","early-phase-1-investigating-the-safety-and-regenerative-potential-of-msc-derived-secretome-combined-with-prgf-in-knee-osteoarthritis-100605082","NCT07157891","Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis","PRGFSECKOA","Inclusion Criteria:\n\n* Following is the inclusion criteria for the enrolment of patients affected with damaged cartilage in this study:\n\n  * Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria\n  * Grade I and II Arthritis\n  * Joint pain ≥ 20mm measured by visual analogue scale\n  * Age ranges from 30-55 years of age\n  * BMI 27.12 ± 4.38\n  * Patients with no previous surgical interventions to lower limb\n  * Willing to participate in the study\n\nExclusion Criteria:\n\n* • Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee\n\n  * Diagnosed with a systemic autoimmune disorder, immunodeficiency or coagulation disorder\n  * Had history of malignancy\n  * History of allergy or allergic constitution\n  * Pregnant or breastfeeding women.","30 Years","55 Years",{"count":136,"type":21},25,[138],"EARLY_PHASE1","This Phase I\u002FII randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.",[141,142,143],"Osteoarthritis (OA)","Knee Injury","Cartilage Degeneration",[145,146,147,148,149,150,151],"Mesenchymal Stem Cell Secretome","Plasma Rich in Growth Factors (PRGF)","Platelet-Rich Plasma (PRP)","Knee Osteoarthritis","Intra-articular Injection","Cell-free Therapy","Regenerative Medicine","2025-08-28",{"date":154,"type":44},"2025-09-05",{"date":156,"type":21},"2025-12-10",{"date":158,"type":21},"2028-12-11",{"name":50,"class":51},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":109,"minAge":168,"maxAge":110,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":90},"100595090","a-feasibility-trial-of-eye-movement-desensitization-and-reprocessing-therapy--integrative-treatment-group-protocol-for-ongoing-traumatic-stress-in-road-traffic-accident-survivors-for-reduction-of-post-traumatic-stress-symptoms-100595090","NCT07027930","A Feasibility Trial of Eye Movement Desensitization and Reprocessing Therapy- Integrative Treatment Group Protocol for Ongoing Traumatic Stress In Road Traffic Accident Survivors for Reduction of Post-traumatic Stress Symptoms","A Feasibility Trial of Eye Movement Desensitization and Reprocessing Therapy- Integrative Treatment Group Protocol for Ongoing Traumatic Stress in Road Traffic Accident Survivors for Reduction of Post-Traumatic Stress Symptoms","EMDR-IGTP-OTS","Inclusion Criteria:\n\n* Aged between 18 and 45 years.\n* Experienced a traffic accident 3 months to 10 years prior\n* Willing to participate and able to understand the intervention components.\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if they meet any of the following criteria:\n\n  * Diagnosed with conditions such as schizophrenia or bipolar disorder, which require specialized treatment beyond the scope of this study.\n  * History of severe head injuries resulting in neurological or cognitive deficits.\n  * Participants who have experienced a traffic accident less than 3 months ago, as immediate post-traumatic responses may not have stabilized","18 Years",{"count":170,"type":21},35,[24],"Road traffic accidents (RTAs) are a significant public health concern globally, accounting for a substantial proportion of morbidity and mortality. This study evaluates the feasibility and acceptability of the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol for Ongoing Traumatic Stress (EMDR-IGTP-OTS) in the reduction of posttraumatic stress symptoms, depression, and anxiety, while improving the quality of life in individuals who have experienced traffic accidents. Using a randomized control design, participants aged 18-45 will be assessed at three-time points: pre-treatment, post-treatment, and one-month follow-up. The study employs the DASS-21, UIES-R, and WHOQOL-BREF as evaluation measures. Findings aim to expand evidence on trauma-focused interventions and explore their applicability in culturally diverse, resource-constrained settings.",[174,175,176],"Post Traumatic Stress Symptoms","Quality of Life (QOL)","Stress","2025-06-16",{"date":179,"type":44},"2025-06-19",{"date":181,"type":44},"2025-05-01",{"date":183,"type":21},"2025-11-01",{"name":50,"class":51},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":109,"minAge":168,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":203,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":90},"100486192","phase-1-efficacy-of-preconditioned-adipose-derived-stem-cells-in-fat-grafting-100486192","NCT05610878","Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting","Supplementation of Autologous Fat Grafts with Curcumin Preconditioned Adipose-Derived Stem Cells in the Treatment of Facial Contour Deformities","Inclusion criteria\n\n* Age 18-50 years (male or female)\n* Body-mass index 20-30 kg\u002Fm²\n* Suitable for liposuction as assessed by the expected cosmetic results\n* Provided signed informed consent\n\nExclusion criteria\n\n* Systemic disorders include autoimmune diseases, hemorrhagic diseases, bone marrow aplasia, sepsis, cancer, and others\n* Local disorders include acne, infections and others\n* Risk factors include smoking, uncompensated diabetes, hypertension, and allergy to the drugs used for general anesthesia\n* Microbiological contamination of either the cell culture or the transplanted tissue","50 Years",{"count":194,"type":21},24,[196],"PHASE1","The aim of this study is to evaluate the comparison of therapeutic potential of curcumin preconditioned adipose derived stem cells (ASCs) enrichment fat grafting, naïve ASCs enrichment fat grafting and conventional fat grafting to correct facial contour deformities that cause aesthetic complications in patients.",[199,200,201,202],"Romberg Disease","Craniofacial Microsomia","Burn Scar","Post-Traumatic Scar (Disorder)",[204,205,206,207],"Facial deformities","Fat grafting","Adipose derived stem cells","Preconditioning","2024-12-30",{"date":210,"type":44},"2024-12-31",{"date":212,"type":44},"2020-11-20",{"date":214,"type":21},"2025-12",{"name":50,"class":51},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":109,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":241,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":246,"locationsCount":90},"100486191","phase-1-efficacy-of-adipose-tissue-derived-stem-cells-for-the-treatment-of-diabetic-foot-ulcers-100486191","NCT05610865","Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers","Autologous Adipose Tissue Derived Stromal Vascular Fraction Versus Cultured Adipose Derived Stem Cells for the Treatment of Chronic Diabetic Wounds","Inclusion Criteria:\n\n* Type 1 or Type 2 Diabetes Mellitus\n* Age 20-60 years (Male\u002FFemale)\n* Body mass index 20-30 kg\u002Fm2\n* Suitable for liposuction\n* Condition or Disease: Diabetic Neuropathy\n* Wound Type: Chronic foot ulcer\n* Approx. wound area: 2 cm2 - 8 cm2\n* Wound Condition should be of Wagner's grade I (Limited to soft tissue)\n* Duration of wound persistence: 6-24 Weeks\n* Transcutaneous oxygen pressure \\> 30 mmHg, and an ankle brachial pressure index \\> 0.5.\n* Already following an adequate off-loading method\n* Provided signed informed consent\n\nExclusion Criteria:\n\n* Uncontrolled hyperglycemia (HbAlc \\> 9%)\n* Presence of severe clinical sign of infection\n* Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.\n* Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases\n* Patients with critical limb ischemia and osteomylitis\n* Withdrawal of informed consent","20 Years","60 Years",{"count":226,"type":21},28,[196],"The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.",[230,231,232,233,234,235,236,237,238,239,240],"Diabetic Foot Ulcer","Diabetes Mellitus","Diabetic Foot","Diabetic Foot Infection","Diabetic Foot Ulcer Neuropathic","Foot Ulcer Due to Type 1 Diabetes Mellitus","Foot Ulcer Due to Type 2 Diabetes Mellitus","Foot Ulcer","Diabetes Complications","Chronic Diabetic Ulcer of Left Foot","Chronic Diabetic Foot Ulcer of Right Foot",[242],"Stromal vascular fraction (SVF), Adipose derived stem cells (ASCs), Diabetic foot ulcer (DFU), Platelet rich plasma (PRP)",{"date":210,"type":44},{"date":212,"type":44},{"date":214,"type":21},{"name":50,"class":51},""]